You are here

Peloton Therapeutics

Merck's Welireg scores FDA nod in cancers spurred by rare disease—and its label is broader than expected

Fierce Pharma

Sat, 08/14/21 - 01:44 pm

Peloton Therapeutics

von Hippel-Lindau disease

Merck wins priority review for rare carcinoma drug belzutifan, the centerpiece of $1B+ Peloton buyout

Endpoints

Tue, 03/16/21 - 10:54 am

Peloton Therapeutics

renal cell carcinoma

priority review

Asco-GU 2020: revving up for Peloton deal validation

EP Vantage

Thu, 02/13/20 - 10:46 am

Peloton Therapeutics

Merck puts $1B more into oncology, with kidney cancer a focus

Biopharma Dive

Wed, 05/22/19 - 09:52 am

Peloton Therapeutics

Merck boosts late-phase cancer pipeline with $1.1B Peloton buy

Fierce Biotech

Tue, 05/21/19 - 09:31 am

Peloton Therapeutics

metastatic renal cell carcinoma

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

Yahoo/Benzinga

Sun, 05/19/19 - 03:59 pm

Bellerophon Therapeutics

Bicycle Therapeutics

Peloton Therapeutics

Peloton Therapeutics Initiates Phase II Trials of Treatment for Rare Kidney Cancer

CP Wire

Wed, 06/6/18 - 09:42 am

Peloton Therapeutics

renal cell carcinoma

Peloton Therapeutics Initiates Phase II Trials of Treatment for Rare Kidney Cancer

Wed, 06/6/18 - 09:33 am

Peloton Therapeutics

renal cell carcinoma